Cystic fibrosis gene correction therapeutic - ReCode Therapeutics
Latest Information Update: 23 Mar 2023
At a glance
- Originator ReCode Therapeutics
- Class Antifibrotics; Gene therapies
- Mechanism of Action Cystic fibrosis transmembrane conductance regulator expression modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cystic fibrosis
Most Recent Events
- 10 Mar 2023 Cystic fibrosis gene correction therapeutic - ReCode Therapeutics is available for licensing as of 10 Mar 2023. https://recodetx.com/partnering/
- 10 Mar 2023 Preclinical trials in Cystic fibrosis in USA (IV), before March 2023 (ReCode Therapeutics pipeline, March 2023)